FindMyKOL
Clinical trialNCT04722172Active, not recruitingPhase 2Interventional

A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

SponsorMemorial Sloan Kettering Cancer CenterEnrollment55Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will test the safety of limiting treatment time with acalabrutinib and obinutuzumab in people who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The researchers want to find out whether stopping the study drugs when the cancer responds to the treatment, followed by a period of observation in which no treatment is given, is better than, the same as, or worse than the usual approach. A usual treatment for CLL and SLL is to give the study drugs continuously until the cancer progresses, even if the disease is in remission. But when people receive these drugs for long periods of time, they can have serious side effects and their cancer can become resistant to treatment.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering Basking Ridge (all Protocol Activities)

    Basking Ridge, New Jersey, United States

  • Hackensack Meridian Health (data Collection Only)

    Hackensack, New Jersey, United States

  • Memorial Sloan Kettering Monmouth (all Protocol Activities)

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen (all Protocol Activities)

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Commack (all Protocol Activities)

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester (all Protocol Activities)

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center (all Protocol Activities)

    New York, New York, United States

  • Memorial Sloan Kettering Nassau (all Protocol Activities)

    Uniondale, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Acalabrutinib →Obinutuzumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 May 2021
Primary completion
28 Feb 2027
Completion
28 Feb 2027
Last update posted
4 Jun 2026
Registered enrollment
55
Registry id
NCT04722172
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.